Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776952 | 0.88 | CHRNA7 (0.76) | ALDH1A1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL20472469 | 0.88 | CHRNA7 (0.76) | ALDH1A1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL9835452 | 0.86 | CHRNA7 (0.61) | ALDH1A1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL27322095 | 0.86 | CHRNA7 (0.61) | ALDH1A1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL1091582 | 0.85 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL13170074 | 0.85 | MEN1 (0.60) | ALDH1A1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL10970540 | 0.82 | CHRNA7 (0.60) | ALDH1A1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL7174499 | 0.82 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL4006377 | 0.82 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ACHRNA7TRPV1 | |
| SCHEMBL31492222 | 0.82 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ACHRNA7TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345893-B1 | UREA DERIVATIVE AND USE THEREFOR | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10280145-B2 | Urea derivative and use therefor | TORAY INDUSTRIES, INC. (JP) | 2019-05-07 | — | — | US | disclosed |
| US-20180237398-A1 | UREA DERIVATIVE AND USE THEREFOR | TORAY INDUSTRIES, INC. (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3345893-A1 | UREA DERIVATIVE AND USE THEREFOR | Toray Industries, Inc. (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1765823-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORP (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7563791-B2 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1765823-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121147-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | ALDH1A1 2803/4885MEN1 2033/4885KMT2A 1484/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ALDH1A1 2988/4885MEN1 3221/4885KMT2A 2544/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ALDH1A1 2803/4885MEN1 2033/4885KMT2A 1484/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ALDH1A1 2803/4885MEN1 2033/4885KMT2A 1484/4885 |
| US-20100075958-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | ALDH1A1 3300/4885MEN1 3457/4885KMT2A 1898/4885 |
| US-10280145-B2 | Urea derivative and use therefor | UTS2R, DDR1, WEE1 | ALDH1A1 1393/4885MEN1 603/4885KMT2A 3875/4885 |
| US-20130225809-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | MKI67, TK2, CDK4 | ALDH1A1 3300/4885MEN1 3457/4885KMT2A 1898/4885 |
| US-20070208013-A1 | 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents | MKI67, CCNA1, CCNI | ALDH1A1 2157/4885MEN1 3851/4885KMT2A 1791/4885 |
| US-20180237398-A1 | UREA DERIVATIVE AND USE THEREFOR | UTS2R, DDR1, WEE1 | ALDH1A1 1393/4885MEN1 603/4885KMT2A 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.